Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	467	((514/259.31) or (544/281)).CCLS.	US-PGPUB; USPAT	OR	OFF	2005/11/02 12:34
L2	31	L1 and ("[1,5-a]pyrimidin" "[1,5-a]" "(1,5-a)")	US-PGPUB; USPAT	OR	ON	2005/11/02 12:34

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1611txm

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available
NEWS 4	AUG 11	STN AnaVist workshops to be held in North America
NEWS 5	AUG 30	CA/CAplus -Increased access to 19th century research documents
NEWS 6	AUG 30	CASREACT - Enhanced with displayable reaction conditions
NEWS 7	SEP 09	ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 8	OCT 03	MATHDI removed from STN
NEWS 9	OCT 04	CA/CAplus-Canadian Intellectual Property Office (CIPO) added to core patent offices
NEWS 10	OCT 06	STN AnaVist workshops to be held in North America
NEWS 11	OCT 13	New CAS Information Use Policies Effective October 17, 2005
NEWS 12	OCT 17	STN(R) AnaVist(TM), Version 1.01, allows the export/download of CAplus documents for use in third-party analysis and visualization tools
NEWS 13	OCT 27	Free KWIC format extended in full-text databases
NEWS 14	OCT 27	DIOGENES content streamlined
NEWS 15	OCT 27	EPFULL enhanced with additional content

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:44:41 ON 02 NOV 2005

=> file reg

FILE 'REGISTRY' ENTERED AT 13:44:54 ON 02 NOV 2005

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 31 OCT 2005 HIGHEST RN 866452-21-3
DICTIONARY FILE UPDATES: 31 OCT 2005 HIGHEST RN 866452-21-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10654546.str





chain nodes :
10 11 14 15 16
ring nodes :
1 2 3 4 5 6 7 8 9
ring/chain nodes :
17
chain bonds :
1-14 6-10 7-16 8-11 10-15 10-17
ring bonds :

```
1-2  1-6  2-3  3-4  4-5  4-7  5-6  5-9  7-8  8-9
exact/norm bonds :
1-2  1-6  1-14  2-3  3-4  4-5  5-6  5-9  6-10  7-16  8-9  10-17
exact bonds :
4-7  7-8  8-11  10-15
isolated ring systems :
containing 1 :


G1:X,H,CH3,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu

G2:Cl,Et

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:CLASS  14:CLASS  15:CLASS  16:CLASS  17:CLASS



L1      STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 13:45:16 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      140 TO ITERATE

100.0% PROCESSED      140 ITERATIONS                                3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          2091 TO     3509
PROJECTED ANSWERS:                3 TO      163

L2            3 SEA SSS SAM L1

=> d scan

L2   3 ANSWERS   REGISTRY  COPYRIGHT 2005 ACS on STN
IN   Pyrazolo[1,5-a]pyrimidin-7-amine, 3-chloro-5-(2-fluorophenyl)-N-4-
     pyridinyl- (9CI)
MF   C17 H11 Cl F N5
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L2 3 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2-Piperidineethanol, 1-[3-ethyl-7-[(3-pyridinylmethyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]-, (2S)- (9CI)
MF C21 H28 N6 O

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 3 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-ethyl-5-methyl-N-propyl- (9CI)
MF C12 H18 N4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l1 full; file caplus; s l3; s us-5602137?/pn; s GB-1412017?/pn
FULL SEARCH INITIATED 13:47:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2964 TO ITERATE

```
100.0% PROCESSED     2964 ITERATIONS                          86 ANSWERS
SEARCH TIME: 00.00.01

L3            86 SEA SSS FUL L1


FILE 'CAPLUS' ENTERED AT 13:47:23 ON 02 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 2 Nov 2005  VOL 143 ISS 19
FILE LAST UPDATED: 1 Nov 2005  (20051101/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html


L4            16 L3


L5             1 US-5602137?/PN
                 (US5602137?/PN)


L6             1 GB-1412017?/PN
                 (GB1412017?/PN)

=> s l4 not l5 not l6
L7            14 L4 NOT L5 NOT L6

=> sort l7 py
SORT ENTIRE ANSWER SET? (Y)/N:.
PROCESSING COMPLETED FOR L7
L8            14 SORT L7 PY

=> d 1-14 cbib pi fhitstr

L8   ANSWER 1 OF 14  CAPLUS  COPYRIGHT 2005 ACS on STN
1982:85506   Document No. 96:85506  Synthesis and enzymic activity of
     6-carbethoxy- and 6-ethoxy-3,7-disubstituted pyrazolo[1,5-a]pyrimidines
     and related derivatives as adenosine cyclic 3',5'-phosphate
     phosphodiesterase inhibitors.  Springer, Robert H.; Scholten, M. B.;
     O'Brien, Darrell E.; Novinson, Thomas; Miller, Jon P.; Robins, Roland K.
     (Viratek, Inc., Covina, CA, 91722, USA).  Journal of Medicinal Chemistry,
     25(3), 235-42 (English) 1982.  CODEN: JMCMAR.  ISSN: 0022-2623.
```

IT **43024-55-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and phosphodiesterase inhibition activity of)
RN 43024-55-1 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-ethyl-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
1996:196727 Document No. 124:261026 Preparation and formulation of pyrazolopyrimidine derivatives as analgesics. Shoji, Yasuo; Inoue, Makoto; Okamura, Takashi; Hashimoto, Kinji; Ohara, Masayuki; Yasuda, Tsuneo (Otsuka Pharmaceutical Factory, Inc., Japan). PCT Int. Appl. WO 9535298 A1 19951228, 89 pp. DESIGNATED STATES: W: AU, CA, CN, KR, US; RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (Japanese). CODEN: PIXXD2. APPLICATION: WO 1995-JP1104 19950605. PRIORITY: JP 1994-138635 19940621; JP 1995-53997 19950314.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9535298	A1	19951228	WO 1995-JP1104	19950605
	W: AU, CA, CN, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2169719	AA	19951228	CA 1995-2169719	19950605
	CA 2169719	C	20020416		
	AU 9525765	A1	19960115	AU 1995-25765	19950605
	AU 680370	B2	19970724		
	EP 714898	A1	19960605	EP 1995-920260	19950605
	EP 714898	B1	20011114		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CN 1131948	A	19960925	CN 1995-190760	19950605
	CN 1046730	B	19991124		
	JP 08311068	A2	19961126	JP 1995-137878	19950605
	JP 3163412	B2	20010508		
	JP 08310951	A2	19961126	JP 1995-137890	19950605
	JP 3163413	B2	20010508		
	AT 208776	E	20011115	AT 1995-920260	19950605
	ES 2164153	T3	20020216	ES 1995-920260	19950605
	PT 714898	T	20020429	PT 1995-920260	19950605
	US 5707997	A	19980113	US 1996-602824	19960221

IT **174859-29-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyrimidine derivs. as analgesics)
RN 174859-29-1 CAPLUS
CN Benzamide, N-(5-butyl-3-chloropyrazolo[1,5-a]pyrimidin-7-yl)-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)



L8 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
1998:246630 Document No. 128:248613 Adenosine reinforcement agents.
Moritoki, Hideki; Iwamoto, Takeshi; Yasuda, Tsuneo (Ootsuka Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP 10101672 A2 19980421 Heisei, 22 pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 1997-208772 19970804. PRIORITY: JP 1996-207171 19960806.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10101672	A2	19980421	JP 1997-208772	19970804

IT **174859-29-1**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adenosine reinforcement agents)
RN 174859-29-1 CAPLUS
CN Benzamide, N-(5-butyl-3-chloropyrazolo[1,5-a]pyrimidin-7-yl)-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)



L8 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
1998:246629 Document No. 128:248612 Nitrogen monooxide synthase inhibitors.

Moritoki, Hideki; Iwamoto, Takeshi; Yasuda, Tsuneo (Ootsuka Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP 10101671 A2 19980421 Heisei, 25 pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 1997-207867 19970801. PRIORITY: JP 1996-209465 19960808.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 10101671	A2	19980421	JP 1997-207867	19970801

IT **174859-29-1**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pyrozolopyrimidine derivs. as nitrogen monooxide synthase inhibitors)
RN 174859-29-1 CAPLUS
CN Benzamide, N-(5-butyl-3-chloropyrazolo[1,5-a]pyrimidin-7-yl)-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)



L8 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
1999:467208 Document No. 131:237490 Synthesis and structure-activity relationship of a new series of potent angiotensin II receptor antagonists: pyrazolo[1,5-a]pyrimidine derivatives. Shiota, Takeshi; Yamamori, Teruo; Sakai, Katsunori; Kiyokawa, Mitsugu; Honma, Tsunetoshi; Ogawa, Masayoshi; Hayashi, Kunio; Ishizuka, Natsuki; Matsumura, Ken-Ichi; Hara, Mariko; Fujimoto, Masafumi; Kawabata, Tomoji; Nakajima, Shigeyuki (Shionogi Research Laboratories, Shionogi and Co., Ltd., Osaka, 553-0002, Japan). Chemical & Pharmaceutical Bulletin, 47(7), 928-938 (English) 1999. CODEN: CPBTAL. ISSN: 0009-2363. Publisher: Pharmaceutical Society of Japan.

IT **167371-47-3P**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(synthesis and structure-activity relationship of pyrazolo[1,5-a]pyrimidines as angiotensin II receptor antagonists)
RN 167371-47-3 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-chloro-5-ethyl-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
2004:878151 Document No. 141:366243 Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors. Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.; Mallams, Alan; Alvarez, Carmen S.; Keertikar, Kartik M.; Rivera, Jocelyn; Chan, Tin-Yau; Madison, Vincent; Fischmann, Thierry O.; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon; Paradkar, Vidyadhar M.; Hobbs, Douglas Walsh (Schering Corporation, USA; Pharmacopeia, Inc.). U.S. Pat. Appl. Publ. US 2004209878 A1 20041021, 1044 pp., Cont.-in-part of US Ser. No. 654,546 (English). CODEN: USXXCO. APPLICATION: US 2004-776988 20040211. PRIORITY: US 2002-2002/PV40802U 20020904; US 2002-2002/PV42195U 20021029; US 2003-2003/654546 20030903.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004209878	A1	20041021	US 2004-776988	20040211
	US 2004209878	A1	20041021	US 2004-776988	20040211
	US 2004209878	A1	20041021	US 2004-776988	20040211
	WO 2005077954	A2	20050825	WO 2005-US3859	20050208

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

IT **672317-36-1P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)
RN 672317-36-1 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(6-chloro-1-oxido-3-pyridinyl)methyl]-3-ethyl-5-phenyl- (9CI) (CA INDEX NAME)



L8 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

2004:857603 Document No. 141:332189 Pyrazolopyrimidine compounds and their use in medicine. Parratt, Martin; Bower, Justin Fairfield; Williamson, Douglas; Cansfield, Andrew (Vernalis Cambridge Limited, UK). PCT Int. Appl. WO 2004087707 A1 20041014, 90 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2004-GB1214 20040318. PRIORITY: GB 2003-7389 20030331; GB 2003-12296 20030529; GB 2003-19028 20030813; GB 2003-25854 20031105.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004087707	A1	20041014	WO 2004-GB1214	20040318

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

IT **771500-11-9P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of aminopyrazolopyrimidines with kinase inhibitory activity)

RN 771500-11-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-chloro-3-ethyl-N-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
2004:740331 Document No. 141:260763 Preparation of pyrazolo[1,5-a]pyrimidines for treating or preventing protein kinase mediated disorders. Kataoka, Kenichiro; Suzuki, Naotaka; Kosugi, Tomomi; Imai, Minoru; Makino, Hiroaki; Takakuwa, Mika; Unoki, Gen; Fujino, Aiko; Oue, Yasuhiro; Yamakoshi, Yuko; Sugiura, Satoshi; Mitchell, Dale Robert; Simpson, Donald James; Harris, Clifford John; Le, Joelle (Teijin Pharma Limited, Japan). PCT Int. Appl. WO 2004076458 A1 20040910, 380 pp. DESIGNATED STATES: W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, ML, MR, NE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2004-JP2522 20040301. PRIORITY: GB 2003-4665 20030228; US 2003-2003/PV50069G 20030908; GB 2003-29446 20031219.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004076458	A1	20040910	WO 2004-JP2522	20040301

W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

IT **754204-59-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolo[1,5-a]pyrimidines for treating or preventing protein kinase mediated disorders)
RN 754204-59-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-5,7-diamine, N5-(trans-4-aminocyclohexyl)-3-chloro-N7-(3-chloro-4-fluorophenyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L8 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
2004:269996 Document No. 140:303691 Preparation and pharmaceutical compositions of novel pyrazolopyrimidines as cyclin dependent kinase inhibitors. Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor Moopil; Alvarez, Carmen S.; Chan, Tin-Yau; Knutson, Chad; Madison, Vincent; Fischmann, Thierry O.; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon (Schering Corporation, USA; Pharmacopeia, Inc.). PCT Int. Appl. WO 2004026229 A2 20040401, 91 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-US27491 20030903. PRIORITY: US 2002-2002/PV408029 20020904.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004026229	A2	20040401	WO 2003-US27491	20030903
WO 2004026229	A3	20040617		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2497544	AA	20040401	CA 2003-2497544	20030903
US 2004106624	A1	20040603	US 2003-653776	20030903
EP 1534712	A2	20050601	EP 2003-796321	20030903
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

IT **676366-35-1P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of pyrazolopyrimidines as cyclin dependent kinase inhibitors)

RN 676366-35-1 CAPLUS

CN Benzenesulfonic acid, 4-[(3-ethyl-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]- (9CI) (CA INDEX NAME)



L8 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

2004:220336 Document No. 140:270873 Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors. Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor Moopil; Mallams, Alan; Alvarez, Carmen S.; Keertikar, Kartik M.; Rivera, Jocelyn; Chan, Tin-yau; Madison, Vincent; Fischmann, Thierry O.; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon; Paradkar, Vidyadhar M.; Hobbs, Douglas Walsh (Schering Corporation, USA; Pharmacopeia, Inc.). PCT Int. Appl. WO 2004022561 A1 20040318, 609 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-US27555 20030903. PRIORITY: US 2002-2002/PV40802U 20020904; US 2002-2002/PV421959 20021029.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004022561	A1	20040318	WO 2003-US27555	20030903
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2497440	AA	20040318	CA 2003-2497440	20030903
	EP 1537116	A1	20050608	EP 2003-794592	20030903
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003014001	A	20050705	BR 2003-14001	20030903

IT **672317-36-1P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)
RN 672317-36-1 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(6-chloro-1-oxido-3-pyridinyl)methyl]-3-ethyl-5-phenyl- (9CI) (CA INDEX NAME)



L8 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
2004:220334 Document No. 140:270871 Preparation of pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors and anticancer agents. Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor Moopil; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon (Schering Corporation, USA; Pharmacopeia, Inc.). PCT Int. Appl. WO 2004022559 A1 20040318, 83 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-US27405 20030903. PRIORITY: US 2002-2002/PV408030 20020904.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004022559	A1	20040318	WO 2003-US27405	20030903
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2497444	AA	20040318	CA 2003-2497444	20030903
US 2004102451	A1	20040527	US 2003-654157	20030903
EP 1534709	A1	20050601	EP 2003-749317	20030903

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

IT **674334-44-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors and anticancer agents for treating diseases, in particular various cancers, associated with cyclin dependent kinase)

RN 674334-44-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-chloro-5-(2-fluorophenyl)-N-3-pyridinyl- (9CI) (CA INDEX NAME)



L8 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

2004:220207 Document No. 140:270868 Preparation of pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors and anticancer agents. Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor Moopil; Knutson, Chad; Mckittrick, Brian; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon (Schering Corporation, USA; Pharmacopeia, Inc.). PCT Int. Appl. WO 2004022062 A1 20040318, 77 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-US27564 20030903. PRIORITY: US 2002-2002/PV408182 20020904.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004022062	A1	20040318	WO 2003-US27564	20030903
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2497539	AA	20040318	CA 2003-2497539	20030903
	US 2004102452	A1	20040527	US 2003-654163	20030903
	EP 1545533	A1	20050629	EP 2003-794594	20030903

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

IT **674297-73-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors and anticancer agents for treating diseases, in particular various cancers, associated with cyclin dependent kinase)

RN 674297-73-5 CAPLUS
CN Carbamic acid, (3-ethyl-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)-, 3-pyridinyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
2005:232568 Document No. 142:291383 Nitrosated and nitrosylated cardiovascular compounds, compositions, and methods of therapeutic use. Garvey, David S.; Letts, Gordon L.; Worcel, Manuel (Nitromed, Inc., USA). PCT Int. Appl. WO 2005023182 A2 20050317, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2004-US26910 20040820. PRIORITY: US 2003-2003/PV49830U 20030828; US 2004-2004/PV535542 20040112.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005023182	A2	20050317	WO 2004-US26910	20040820

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,

SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005059655 A1 20050317 US 2004-921936 20040820

WO 2005023183 A2 20050317 WO 2004-US26911 20040820

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

IT **167371-59-7D**, nitrosated/nitrosylated derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nitrosated and nitrosylated cardiovascular compds., compns., and therapeutic use)

RN 167371-59-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3,5-diethyl-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

2005:86349 Document No. 142:253677 Structure-guided design of pyrazolo[1,5-a]pyrimidines as inhibitors of human cyclin-dependent kinase 2. Williamson, Douglas S.; Parratt, Martin J.; Bower, Justin F.; Moore, Jonathan D.; Richardson, Christine M.; Dokurno, Pawel; Cansfield, Andrew D.; Francis, Geraint L.; Hebdon, Richard J.; Howes, Rob; Jackson, Philip S.; Lockie, Andrea M.; Murray, James B.; Nunns, Claire L.; Powles, Jenifer; Robertson, Alan; Surgenor, Allan E.; Torrance, Christopher J. (Granta Park, Vernalis (R&D) Ltd., Cambridge, CB1 6GB, UK). Bioorganic & Medicinal Chemistry Letters, 15(4), 863-867 (English) 2005. CODEN: BMCLE8. ISSN: 0960-894X. OTHER SOURCES: CASREACT 142:253677. Publisher: Elsevier B.V..

IT **771506-60-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(structure-guided design of pyrazolo[1,5-a]pyrimidines as CDK2 inhibitors)
RN 771506-60-6 CAPLUS
CN Benzenesulfonamide, 4-[[5-[(trans-4-aminocyclohexyl)amino]-3-chloropyrazolo[1,5-a]pyrimidin-7-yl]amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



=>
=> d 1-5 cbib pi hitstr

L8 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
1982:85506 Document No. 96:85506 Synthesis and enzymic activity of 6-carbethoxy- and 6-ethoxy-3,7-disubstituted pyrazolo[1,5-a]pyrimidines and related derivatives as adenosine cyclic 3',5'-phosphate phosphodiesterase inhibitors. Springer, Robert H.; Scholten, M. B.; O'Brien, Darrell E.; Novinson, Thomas; Miller, Jon P.; Robins, Roland K. (Viratek, Inc., Covina, CA, 91722, USA). Journal of Medicinal Chemistry, 25(3), 235-42 (English) 1982. CODEN: JMCMAR. ISSN: 0022-2623.
IT **43024-55-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and phosphodiesterase inhibition activity of)
RN 43024-55-1 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-ethyl-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
1996:196727 Document No. 124:261026 Preparation and formulation of

pyrazolopyrimidine derivatives as analgesics. Shoji, Yasuo; Inoue, Makoto; Okamura, Takashi; Hashimoto, Kinji; Ohara, Masayuki; Yasuda, Tsuneo (Otsuka Pharmaceutical Factory, Inc., Japan). PCT Int. Appl. WO 9535298 A1 19951228, 89 pp. DESIGNATED STATES: W: AU, CA, CN, KR, US; RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (Japanese). CODEN: PIXXD2. APPLICATION: WO 1995-JP1104 19950605. PRIORITY: JP 1994-138635 19940621; JP 1995-53997 19950314.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9535298	A1	19951228	WO 1995-JP1104	19950605
	W: AU, CA, CN, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2169719	AA	19951228	CA 1995-2169719	19950605
	CA 2169719	C	20020416		
	AU 9525765	A1	19960115	AU 1995-25765	19950605
	AU 680370	B2	19970724		
	EP 714898	A1	19960605	EP 1995-920260	19950605
	EP 714898	B1	20011114		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CN 1131948	A	19960925	CN 1995-190760	19950605
	CN 1046730	B	19991124		
	JP 08311068	A2	19961126	JP 1995-137878	19950605
	JP 3163412	B2	20010508		
	JP 08310951	A2	19961126	JP 1995-137890	19950605
	JP 3163413	B2	20010508		
	AT 208776	E	20011115	AT 1995-920260	19950605
	ES 2164153	T3	20020216	ES 1995-920260	19950605
	PT 714898	T	20020429	PT 1995-920260	19950605
	US 5707997	A	19980113	US 1996-602824	19960221

IT **174859-29-1P 174859-31-5P 174859-32-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyrimidine derivs. as analgesics)

RN 174859-29-1 CAPLUS
CN Benzamide, N-(5-butyl-3-chloropyrazolo[1,5-a]pyrimidin-7-yl)-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)



RN 174859-31-5 CAPLUS
CN Benzamide, N-(5-butyl-3-chloropyrazolo[1,5-a]pyrimidin-7-yl)-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 174859-32-6 CAPLUS
CN Benzamide, N-(3-chloropyrazolo[1,5-a]pyrimidin-7-yl)-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)



L8 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
1998:246630 Document No. 128:248613 Adenosine reinforcement agents.
Moritoki, Hideki; Iwamoto, Takeshi; Yasuda, Tsuneo (Ootsuka Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP 10101672 A2 19980421 Heisei, 22 pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 1997-208772 19970804. PRIORITY: JP 1996-207171 19960806.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10101672	A2	19980421	JP 1997-208772	19970804

IT **174859-29-1 205041-84-5**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adenosine reinforcement agents)
RN 174859-29-1 CAPLUS
CN Benzamide, N-(5-butyl-3-chloropyrazolo[1,5-a]pyrimidin-7-yl)-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)



RN 205041-84-5 CAPLUS
CN Benzamide, N-(5-butyl-3-chloropyrazolo[1,5-a]pyrimidin-7-yl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L8 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
1998:246629 Document No. 128:248612 Nitrogen monooxide synthase inhibitors. Moritoki, Hideki; Iwamoto, Takeshi; Yasuda, Tsuneo (Ootsuka Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP 10101671 A2 19980421 Heisei, 25 pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 1997-207867 19970801. PRIORITY: JP 1996-209465 19960808.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10101671	A2	19980421	JP 1997-207867	19970801

IT **174859-29-1 205041-84-5**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pyrozolopyrimidine derivs. as nitrogen monooxide synthase inhibitors)
RN 174859-29-1 CAPLUS
CN Benzamide, N-(5-butyl-3-chloropyrazolo[1,5-a]pyrimidin-7-yl)-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)



RN 205041-84-5 CAPLUS
CN Benzamide, N-(5-butyl-3-chloropyrazolo[1,5-a]pyrimidin-7-yl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L8 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
1999:467208 Document No. 131:237490 Synthesis and structure-activity relationship of a new series of potent angiotensin II receptor antagonists: pyrazolo[1,5-a]pyrimidine derivatives. Shiota, Takeshi; Yamamori, Teruo; Sakai, Katsunori; Kiyokawa, Mitsugu; Honma, Tsunetoshi; Ogawa, Masayoshi; Hayashi, Kunio; Ishizuka, Natsuki; Matsumura, Ken-Ichi; Hara, Mariko; Fujimoto, Masafumi; Kawabata, Tomoji; Nakajima, Shigeyuki (Shionogi Research Laboratories, Shionogi and Co., Ltd., Osaka, 553-0002, Japan). Chemical & Pharmaceutical Bulletin, 47(7), 928-938 (English) 1999. CODEN: CPBTAL. ISSN: 0009-2363. Publisher: Pharmaceutical Society of Japan.
IT **167371-47-3P 167371-59-7P 244127-03-5P**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(synthesis and structure-activity relationship of pyrazolo[1,5-a]pyrimidines as angiotensin II receptor antagonists)
RN 167371-47-3 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-chloro-5-ethyl-N-[[2'-(1H-tetrazol-5-

yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 167371-59-7 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3,5-diethyl-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 244127-03-5 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-ethyl-5-methyl-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



IT **167371-46-2P 167371-58-6P 244127-50-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and structure-activity relationship of pyrazolo[1,5-a]pyrimidines as angiotensin II receptor antagonists)

RN 167371-46-2 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[[(3-chloro-5-ethylpyrazolo[1,5-a]pyrimidin-7-yl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 167371-58-6 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[[(3,5-diethylpyrazolo[1,5-a]pyrimidin-7-yl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 244127-50-2 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[[(3-ethyl-5-methylpyrazolo[1,5-a]pyrimidin-7-yl)amino]methyl]- (9CI) (CA INDEX NAME)



=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:.

STN INTERNATIONAL LOGOFF AT 13:51:38 ON 02 NOV 2005